Sector Alpha Week of 2026-09-17
Not SEBI Registered !! Not Investment advice !!
Sector Alpha — machine-written from the numbers · Data as of 2026-09-17

Option Care Health, Inc.

OPCH
Healthcare · Medical Care Facilities

Option Care Health, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk.

The price is in a downtrend (21 weeks in) while the P/E sits at the 9th percentile of its own 5-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and 138% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.

Stage
Improving
fundamental trajectory, 12 quarters
Price
$24.5
−13.6% 1Y
P/E
18.5×
9th pctile
of its own 5-year range
Revenue (Mar 26)
$1.4 B
+1.5% YoY
Profit (Mar 26)
$0.1 B
+0.0% YoY
Operating margin
5.2%
−0.8 pp YoY
ROE
16%
FY25
ROIC
10.3%
vs WACC 6.5% → +3.8 pp
Cash conversion
138%
of profit, last 3 FY
01 · Price story

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Option Care Health, Inc. trades at $24.5, in a downtrend and 21 weeks into that stage. That is −9.3% against its own 200-day average. It sits at 30% of a 52-week range of $20 to $36. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 8 straight weeks.

Today the stock is in a downtrend — week 21 of stage 4. At $24.5 it trades −9.3% versus its 200-day average and sits at 30% of its 52-week range ($20–$36).

Sep 26: $24.5 Weekly closing price ($) with 50- and 200-day averages; shaded bands mark the price stage (grey base, green advance, amber top, red decline). 3-year window.
−9.3% versus the 200-day line, week 21 of stage 4
Price50-day avg200-day avg
S1S4S3S1S2S4$37.6$32.8$27.9$23.0$18.2$$25$27Sep 23Jun 24Mar 25Dec 25Sep 26
S1S4S3S1S2S4$37.6$32.8$27.9$23.0$18.2$$25$27Sep 23Mar 25Sep 26
Beating or trailing, week by week since 2019 Each cell is one week from 2019 to now (372 weeks): the stock's trailing 13-week return minus the S&P 500's, green ahead / red behind (±25% ramp). Grey cells are the 13-week warm-up or weeks where the S&P 500 reading is not held.
trailing 13-week return vs the S&P 500
Aug 19Sep 26

Against the market, two honest reads. Cumulative: over the last 7.1 years the stock moved +110% while the S&P 500 moved +159% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

02 · Valuation

Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.

Option Care Health, Inc. trades at 18.5× P/E, near the bottom of its own range — cheaper only 9% of the time. Its long-run median P/E is 25.3×, measured across 4.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 18.5× is near the bottom of its own range — cheaper only 9% of the time, against a long-run median of 25.3× measured over 4.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

P/E 18.5× vs a 25.3× long-run median P/E, weekly (left axis); earnings per share, trailing twelve months, weekly step line (right axis). 4.5-year window; loss-period spikes above 37× shown pinned at the top. The eps (ttm) bars are red where the reading is lower than the quarter before.
near the bottom of its own range — cheaper only 9% of the time
P/EMedianEPS (TTM) (quarterly)
39.0×$1.632.6×$1.226.2×$0.819.8×$0.413.4×$0.0×$18.97×$1Apr 22May 23Jun 24Aug 25Sep 26
39.0×$1.632.6×$1.226.2×$0.819.8×$0.413.4×$0.0×$18.97×$1Apr 22Jun 24Sep 26
PEG 1.22 PEG ratio per quarter — the P/E divided by the earnings-growth rate. The dashed line marks 1.0: below it the growth is cheap against the multiple, above it the price already prices the growth in. Last 20 quarters; values above 6 pinned at the top.
above 1.0, the multiple already banks the growth
PEGPEG = 1.0
6.5×4.8×3.2×1.6×0.0××1.22×Sep 21Sep 22Dec 23Mar 25Jun 26
6.5×4.8×3.2×1.6×0.0××1.22×Sep 21Dec 23Jun 26
P/E
18.5×
9th percentile of 5y
PEG
1.47
as reported

Why the multiple sits where it does: over the past year annual EPS moved +3.3% against a −13.6% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 3y, of the −11.1%/yr price move, ~−0.5%/yr came from earnings growth and ~−10.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

03 · Stage: Improving

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Option Care Health, Inc. reads as improving on its fundamental arc. Improving — EPS growth bottomed 4 quarters ago at −17.0% and has held its recovery at +4.0%, ROCE holding at 12.2%. The read is built from 12 quarters across 4 curves, on full evidence.

Growth, year by year: revenue +13.0% in FY25, profit +0.0% Year-over-year growth per fiscal year, %: revenue (left axis); net profit and EPS (right axis — profit growth swings far wider). Zero line drawn.
Revenue YoYProfit YoYEPS YoY
17%88%15%59%13%29%11%0.0%8.5%−30%%%13%0%FY21FY23FY25
17%88%15%59%13%29%11%0.0%8.5%−30%%%13%0%FY21FY23FY25
Three growth curves, twelve quarters Year-on-year growth of trailing-twelve-month revenue (left axis), profit and EPS (right axis — they swing far wider), % at each quarter-end. A missing point means that reading is not held for the quarter.
the trajectory the stage is read from · revenue rolling over, profit accelerating
RevenueProfitEPS
18%88%15%58%13%27%11%−3.7%8.2%−34%%%9.4%0%4%Jun 23Sep 24Mar 26
18%88%15%58%13%27%11%−3.7%8.2%−34%%%9.4%0%4%Jun 23Sep 24Mar 26
ROCE Trailing-twelve-month operating profit (before interest and tax) as a share of average capital employed — total assets minus current liabilities, the standard textbook basis, %.
the return curve, computed quarterly
ROCE
13.3%12.7%12.1%11.4%10.8%%12.2%Jun 23Dec 23Sep 24Jun 25Mar 26
13.3%12.7%12.1%11.4%10.8%%12.2%Jun 23Sep 24Mar 26
Revenue growth
Steady high
latest +9.4% · span +8.9% to +17.2%
Profit growth
Flat
latest +0.0% · span −25.9% to +80.0%
EPS growth
Flat
latest +4.0% · span −18.4% to +77.1%
ROCE
Stuck low
latest 12.2% · span 11.0%–13.1%

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

Compound annual growth rate (%) Compound annual growth rate over each window, %. Revenue, profit and EPS from fiscal-year figures; stock price is the price CAGR over the same spans. A dash = that window is not held, or the base was a loss.
1yr3yr5yr10yr
Revenue+13.0%+12.8%
Profit+0.0%+11.9%
EPS+3.3%+15.2%
Stock price−13.6%−11.1%−1.0%
Revenue YoY (Mar 26)
+1.5%
latest quarter vs a year ago
Profit YoY (Mar 26)
+0.0%
latest quarter vs a year ago
Revenue 10y
13.2%
long-run compound pace
04 · 4-Factor Sector Score

4-Factor Sector Score

43.5/100 — rank 21 of 30 in Medical Care Facilities · 58% evidence confidence

Option Care Health, Inc. scores 43.5 out of 100 against the 30 companies it is compared with in Medical Care Facilities, ranking 21. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 17.3 + 11.3 + 9.9 + 5 = 43.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

05 · Revenue

Revenue Revenue is the top line: everything the company billed its customers in the period.

Option Care Health, Inc. reported $1.4 B of revenue in the Mar 26 quarter, +1.5% year on year. That is the 12th straight quarter of year-on-year growth. Over 4 years it has compounded at 13.2% a year. The last full year, FY25, came in at $5.7 B. The last four reported quarters add to $5.7 B.

FY25 revenue came in at $5.7 B (+13.0% on the year), capping 4 years at 13.2% compound. The latest quarter (Mar 26) printed $1.4 B, +1.5% year on year — the 12th consecutive quarter of year-over-year growth.

FY25 revenue $5.7 B (+13.0% YoY) Revenue bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
13.2% a year over 4 years
RevenueYoY growth
6.117%4.615%3.113%1.511%0.08.5%$ B%$6B13%FY21FY23FY25
6.117%4.615%3.113%1.511%0.08.5%$ B%$6B13%FY21FY23FY25
Mar 26: $1.4 B (+1.5% YoY) Quarterly revenue bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
12th straight quarter of growth
Revenue (quarterly)YoY growth
1.622%1.217%0.811%0.45.5%0.00.0%$ B%$1B1.5%Jun 23Sep 24Mar 26
1.622%1.217%0.811%0.45.5%0.00.0%$ B%$1B1.5%Jun 23Sep 24Mar 26

Pace check: the last four quarters averaged +9.6% growth against the decade's 13.2% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +9.4% over the last 4 quarters against +13.2%/yr over the last 8 — rolling over; TTM profit +0.0% vs −11.8%/yr — accelerating.

06 · Operating margin

Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Option Care Health, Inc.'s operating margin is 5.2% in the Mar 26 quarter, −0.8 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.5% to 7.2%. The current quarter is running below every full year in that window.

The latest quarter's operating margin is 5.2%, −0.8 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 5.5%–7.2%.

🚨 Why the margin moved: operating margin went −0.8 pp year on year while gross margin went −0.2 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

FY25: 6.0% Operating margin by fiscal year, %, line (left); year-on-year change in the margin, in percentage points, line (right). 5-year window.
within a 5.5–7.2% band over 5 years
operating marginYoY change (pp)
7.3%1.3%6.8%0.7%6.3%0.2%5.9%−0.4%5.4%−1.0%%%6%−0.4%FY21FY23FY25
7.3%1.3%6.8%0.7%6.3%0.2%5.9%−0.4%5.4%−1.0%%%6%−0.4%FY21FY23FY25
Mar 26: 5.2% operating margin (−0.8 pp YoY) Quarterly operating margin, %, line (left); year-on-year change in the margin, in percentage points, line (right). Last 12 quarters. Operating profit as a share of revenue, per quarter.
Operating marginYoY change (pp)
7.7%1.6%7.0%0.8%6.3%0.0%5.7%−0.8%5.0%−1.6%%%5.2%−0.8%Jun 23Sep 24Mar 26
7.7%1.6%7.0%0.8%6.3%0.0%5.7%−0.8%5.0%−1.6%%%5.2%−0.8%Jun 23Sep 24Mar 26
07 · Net profit

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Option Care Health, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.2 B. The 4-year compound rate is 10.7%. That is 3.7% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.

Mar 26 profit was $0.1 B, +0.0% year on year. On the full year, FY25 printed $0.2 B (+0.0%), and the 4-year compound rate is 10.7%.

FY25 profit $0.2 B (+0.0% YoY) Net profit bars, $ B (left); YoY growth-% line (right). 5-year window. A bar is red when it is lower than the year before.
10.7% a year over 4 years
Net profitYoY growth
0.2988%0.2259%0.1529%0.070.0%0.00−30%$ B%$0B0%FY21FY23FY25
0.2988%0.2259%0.1529%0.070.0%0.00−30%$ B%$0B0%FY21FY23FY25
Mar 26: $0.1 B (+0.0% YoY) Quarterly net profit bars, $ B (left); YoY growth-% line (right). Last 12 quarters. A bar is red when it is lower than the quarter before.
Net profit (quarterly)YoY growth
0.12292%0.09199%0.06106%0.0313%0.00−80%$ B%$0B0%Jun 23Sep 24Mar 26
0.12292%0.09199%0.06106%0.0313%0.00−80%$ B%$0B0%Jun 23Sep 24Mar 26

🚨 Why profit moved: revenue contributed +1.5% and the margin −0.8 pp — the quarter was revenue-led, with the margin roughly flat.

Pace comparison, last four quarters: profit +0.0% vs revenue +9.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

08 · Cash flow — the router

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 138% of Option Care Health, Inc.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $0.3 B of operating cash against $0.2 B of profit. After $0.0 B of capital spending, $0.2 B was left as free cash.

FY25: operating cash of $0.3 B against reported profit of $0.2 B, leaving free cash of $0.2 B after $0.0 B of capital spending. Across the last 3 fiscal years the conversion rate is 138% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

FY25: CFO $0.3 B vs profit $0.2 B Operating cash flow and net profit by fiscal year, $ B; the line is free cash flow (CFO minus capital spending). 5-year window, annual resolution.
138% of 3-year profit arrived as cash
Operating cashNet profitFree cash
0.40.30.20.10.0$ B$0B$0B$0BFY21FY23FY25
0.40.30.20.10.0$ B$0B$0B$0BFY21FY23FY25
Jun 26: operating cash $0.2 B Operating cash per quarter, $ B (bars); conversion = operating cash as % of net profit (line, right). Last 12 quarters. Dashed line = 100%.
Operating cash (quarterly)Conversion100%
0.22446%0.14279%0.07113%−0.01−54%−0.09−221%$ B%$0B−20%Sep 23Dec 24Jun 26
0.22446%0.14279%0.07113%−0.01−54%−0.09−221%$ B%$0B−20%Sep 23Dec 24Jun 26

Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.

Router verdict: the visible cash user is investment — the next section checks what the spending is buying.

09 · Where the cash goes

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Option Care Health, Inc. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.

Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.

On the investment side: capital spending of $0.0 B over the last 3 fiscal years.

FY25: capex $0.0 B Capital spending per fiscal year, $ B (bars).
steady investment
Capex
0.040.030.020.010.00$ B$0BFY21FY23FY25
0.040.030.020.010.00$ B$0BFY21FY23FY25
Jun 26: capex $0.0 B in the quarter Capital spending per quarter, $ B (bars, left); free cash flow, $ B (line, right). Last 12 quarters.
Capex (quarterly)Free cash
0.0220.210.0160.140.0110.060.005−0.020.000−0.09$ B$ B$0B$0BSep 23Dec 24Jun 26
0.0220.210.0160.140.0110.060.005−0.020.000−0.09$ B$ B$0B$0BSep 23Dec 24Jun 26

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

10 · Return on equity

Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.

Option Care Health, Inc. earns a ROE of 16% in FY25. That is up from a trough of 11% in FY22. Return on invested capital clears the cost of that capital by +3.8 percentage points, so growth here adds value rather than only size. The wiring behind it is 3.7% net margin on 1.63× asset turns.

FY25 ROE is 16%, recovered from a FY22 trough of 11% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY25): 3.7% net margin × 1.63× asset turns × 2.60× balance-sheet leverage ≈ 15.7% on equity. Margin does its share; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 10.3% − 6.5% = a +3.8 pp spread. The 6.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

FY25: ROE 16% Return on equity by fiscal year, % (line); ROIC by fiscal year, % (line). 5-year window, dips included. Dashed line = the 6.5% cost of capital used on this page.
the climb back from FY22's 11%
ROEROIC (annual)WACC
20%16%13%9.1%5.5%%15.8%10.8%FY21FY23FY25
20%16%13%9.1%5.5%%15.8%10.8%FY21FY23FY25
Jun 26: ROIC 10.3% (TTM) vs WACC 6.5% Trailing-twelve-month ROIC and ROE, per quarter, %; dashed line = the cost of capital. Last 12 quarters, put on a trailing-twelve-month basis and anchored to the annual figure.
ROIC (TTM)ROE (TTM)WACC
21%17%13%9.3%5.4%%10.3%15.5%Sep 23Dec 24Jun 26
21%17%13%9.3%5.4%%10.3%15.5%Sep 23Dec 24Jun 26
11 · Dividend

Dividend

Option Care Health, Inc. pays no dividend. Across the last 12 reported quarters it has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings rather than distribute them, which makes the cash-flow and reinvestment sections the place that cash shows up.

Option Care Health, Inc. does not currently pay a dividend. Across the last 12 reported quarters the company has declared no dividend per share, so there is no payout history to chart and no yield to quote. Companies at this stage typically reinvest earnings instead of distributing them.

12 · Debt

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Option Care Health, Inc. carries total debt of $1.3 B against shareholder equity of $1.3 B as of Jun 26, a debt-to-equity of 1.01. On the annual view that ratio went from 0.98 in FY21 to 0.95 in FY25. Read the returns elsewhere on this page with that leverage in mind.

Jun 26: total debt of $1.3 B against shareholder equity of $1.3 B — a debt-to-equity of 1.01. On the annual view, debt-to-equity went from 0.98 (FY21) to 0.95 (FY25). Read the returns on this page with that leverage in mind.

FY25: debt $1.3 B at 0.95× equity Total debt by fiscal year, $ B (bars); debt-to-equity, × (line). 5-year window.
Total debtDebt-to-equity
1.40.99×1.00.95×0.70.90×0.30.85×0.00.81×$ B×$1B0.95×FY21FY23FY25
1.40.99×1.00.95×0.70.90×0.30.85×0.00.81×$ B×$1B0.95×FY21FY23FY25
Jun 26: debt $1.3 B, debt-to-equity 1.01 Total debt per quarter, $ B (bars); debt-to-equity, × (line). Last 12 quarters.
Total debt (quarterly)Debt-to-equity
1.41.03×1.00.97×0.70.91×0.30.85×0.00.79×$ B×$1B1.01×Sep 23Dec 24Jun 26
1.41.03×1.00.97×0.70.91×0.30.85×0.00.79×$ B×$1B1.01×Sep 23Dec 24Jun 26
13 · Ownership

Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.

8.6% of Option Care Health, Inc.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 6.0 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.

The latest reading: 8.6% of the float is sold short, and at typical trading volumes it would take about 6.0 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.

Short interest
8.6%
of the tradable float
Days to cover
6.0
at typical volumes

Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.

14 · Safety line

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Option Care Health, Inc.: the Z-score reads 3.84. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 3.84 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 3.84.

15 · Related companies · Medical Care Facilities
CompanyScorePrice stageGrowth & earnings/35Capital efficiency/25Valuation/20Relative strength/20
1Tenet Healthcare CorporationTHC 65.2/100Thin evidence · provisional58% evidence BREAKING OUT 24.1/35 Revenue — · PAT — · OPM change 6.2 pp 45% evidence 16.4/25 ROCE 5.8% · OPM 23.2% 76% evidence 11.0/20 P/E 7.2× · PEG — 15% evidence 13.7/20 RS sector -3.7% · RS bench 18.8% · 1Y 39.8%9 of 12 weeks ahead 100% evidence
Exact sum: 24.1 + 16.4 + 11 + 13.7 = 65.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
2Concentra Group Holdings Parent, Inc.CON 62.0/100Mixed-positive evidence71% evidence LEADER 19.8/35 Revenue 15.5% · PAT 12.9% · OPM change 0.8 pp 83% evidence 14.7/25 ROCE 3.8% · OPM 16.8% 76% evidence 10.1/20 P/E 15.4× · PEG — 15% evidence 17.4/20 RS sector 13.5% · RS bench 38% · 1Y 76%12 of 12 weeks ahead 100% evidence
Exact sum: 19.8 + 14.7 + 10.1 + 17.4 = 62 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
3Encompass Health CorporationEHC 61.5/100Mixed-positive evidence81% evidence BREAKING OUT 20.8/35 Revenue 10.1% · PAT 21% · OPM change 0.7 pp 83% evidence 15.8/25 ROCE 4.9% · OPM 19% 76% evidence 14.0/20 P/E 16.1× · PEG 0.68 65% evidence 10.9/20 RS sector -15.3% · RS bench 5.4% · 1Y -0.1%8 of 12 weeks ahead 100% evidence
Exact sum: 20.8 + 15.8 + 14 + 10.9 = 61.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
4Addus HomeCare CorporationADUS 56.9/100Mixed-positive evidence81% evidence BREAKING OUT 21.2/35 Revenue 19.5% · PAT 26.6% · OPM change 0.4 pp 83% evidence 12.3/25 ROCE 2.7% · OPM 9.4% 76% evidence 13.4/20 P/E 17.3× · PEG 0.78 65% evidence 10.0/20 RS sector -17.2% · RS bench 3% · 1Y 5.9%11 of 12 weeks ahead 100% evidence
Exact sum: 21.2 + 12.3 + 13.4 + 10 = 56.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
5Nutex Health Inc.NUTX 55.9/100Mixed-positive evidence75% evidence LEADER 17.5/35 Revenue 40.8% · PAT 31.3% · OPM change -0.6 pp 83% evidence 15.9/25 ROCE 12.1% · OPM 37.5% 76% evidence 6.8/20 P/E 6.9× · PEG 2.9 65% evidence 15.7/20 RS sector 20.7% · RS bench 47.8% · 1Y 126.1%11 of 12 weeks ahead 70% evidence
Exact sum: 17.5 + 15.9 + 6.8 + 15.7 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
6LifeStance Health Group, Inc.LFST 55.4/100Mixed-positive evidence64% evidence LEADER 22.4/35 Revenue 16.4% · PAT — · OPM change 5 pp 62% evidence 5.8/25 ROCE 1.2% · OPM 5.5% 76% evidence 8.5/20 P/E 106.2× · PEG — 15% evidence 18.7/20 RS sector 25.5% · RS bench 51.5% · 1Y 144.6%12 of 12 weeks ahead 100% evidence
Exact sum: 22.4 + 5.8 + 8.5 + 18.7 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
7Aveanna Healthcare Holdings Inc.AVAH 54.4/100Thin evidence · provisional58% evidence LEADER 11.7/35 Revenue — · PAT — · OPM change -2.9 pp 45% evidence 11.8/25 ROCE 4.8% · OPM 10.7% 76% evidence 11.4/20 P/E 5.4× · PEG — 15% evidence 19.5/20 RS sector 24.4% · RS bench 53.1% · 1Y 76%12 of 12 weeks ahead 100% evidence
Exact sum: 11.7 + 11.8 + 11.4 + 19.5 = 54.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
8PACS Group, Inc.PACS 53.7/100Thin evidence · provisional56% evidence LEADER 22.2/35 Revenue — · PAT — · OPM change 4.7 pp 39% evidence 13.3/25 ROCE 5.2% · OPM 8.5% 76% evidence 9.1/20 P/E 31.5× · PEG — 15% evidence 9.1/20 RS sector -2.3% · RS bench 18.1% · 1Y 256.9%12 of 12 weeks ahead 100% evidence
Exact sum: 22.2 + 13.3 + 9.1 + 9.1 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
9Chemed CorporationCHE 53.4/100Thin evidence · provisional58% evidence BREAKING OUT 18.2/35 Revenue — · PAT — · OPM change -1.7 pp 45% evidence 15.6/25 ROCE 6.6% · OPM 12.9% 76% evidence 9.3/20 P/E 23.4× · PEG — 15% evidence 10.3/20 RS sector -13.8% · RS bench 6.4% · 1Y 12.7%12 of 12 weeks ahead 100% evidence
Exact sum: 18.2 + 15.6 + 9.3 + 10.3 = 53.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
10Fresenius Medical Care AGFMS 52.9/100Mixed-positive evidence81% evidence ASLEEP 21.9/35 Revenue -0.7% · PAT 43.7% · OPM change 1.5 pp 83% evidence 11.3/25 ROCE 2.1% · OPM 11.7% 76% evidence 15.7/20 P/E 11.9× · PEG 0.22 65% evidence 4.0/20 RS sector -27% · RS bench -9% · 1Y -9.2%5 of 12 weeks ahead 100% evidence
Exact sum: 21.9 + 11.3 + 15.7 + 4 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
11Guardian Pharmacy Services, Inc.GRDN 51.0/100Mixed-positive evidence64% evidence TURNING 17.6/35 Revenue 13.6% · PAT — · OPM change 1.4 pp 62% evidence 12.3/25 ROCE 7.8% · OPM 5.3% 76% evidence 8.7/20 P/E 45.4× · PEG — 15% evidence 12.4/20 RS sector 3% · RS bench 25.9% · 1Y 82.9%2 of 12 weeks ahead 100% evidence
Exact sum: 17.6 + 12.3 + 8.7 + 12.4 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
12HCA Healthcare, Inc.HCA 50.9/100Mixed-positive evidence85% evidence BREAKING OUT 14.6/35 Revenue 7.3% · PAT 14.1% · OPM change -0.7 pp 95% evidence 15.6/25 ROCE 6.9% · OPM 15.2% 76% evidence 15.1/20 P/E 13.1× · PEG 0.51 65% evidence 5.6/20 RS sector -28.6% · RS bench -10.7% · 1Y 7%4 of 12 weeks ahead 100% evidence
Exact sum: 14.6 + 15.6 + 15.1 + 5.6 = 50.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
13Healthcare Services Group, Inc.HCSG 50.8/100Thin evidence · provisional52% evidence FADING 23.0/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence 10.7/25 ROCE 3.6% · OPM 7.3% 76% evidence 10.3/20 P/E 14.3× · PEG — 15% evidence 6.8/20 RS sector -17.5% · RS bench 1.4% · 1Y 38.3%6 of 12 weeks ahead 70% evidence
Exact sum: 23 + 10.7 + 10.3 + 6.8 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
14National HealthCare CorporationNHC 48.7/100Mixed-negative evidence81% evidence LEADER 16.9/35 Revenue 10.3% · PAT 16.7% · OPM change 0.2 pp 83% evidence 10.2/25 ROCE 2.5% · OPM 8.4% 76% evidence 9.8/20 P/E 20.3× · PEG 1.48 65% evidence 11.8/20 RS sector 2.7% · RS bench 24.7% · 1Y 92.3%12 of 12 weeks ahead 100% evidence
Exact sum: 16.9 + 10.2 + 9.8 + 11.8 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
15Universal Health Services, Inc.UHS 48.1/100Thin evidence · provisional58% evidence BREAKING OUT 16.7/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 14.0/25 ROCE 4.1% · OPM 11.2% 76% evidence 11.3/20 P/E 6.1× · PEG — 15% evidence 6.1/20 RS sector -29.4% · RS bench -11.2% · 1Y -3.9%5 of 12 weeks ahead 100% evidence
Exact sum: 16.7 + 14 + 11.3 + 6.1 = 48.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
16agilon health, inc.AGL 47.6/100Mixed-negative evidence61% evidence FADING 18.8/35 Revenue -2.8% · PAT — · OPM change 1.7 pp 62% evidence 4.8/25 ROCE 1% · OPM 0.3% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 14.0/20 RS sector 54% · RS bench 76.9% · 1Y 209.2%8 of 12 weeks ahead 100% evidence
Exact sum: 18.8 + 4.8 + 10 + 14 = 47.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17The Pennant Group, Inc.PNTG 46.7/100Mixed-negative evidence75% evidence LEADER 20.3/35 Revenue 36.6% · PAT 20.7% · OPM change 0.1 pp 83% evidence 9.2/25 ROCE 2.3% · OPM 6.1% 76% evidence 4.0/20 P/E 35.9× · PEG 3.03 65% evidence 13.2/20 RS sector 1.7% · RS bench 24.3% · 1Y 76.1%11 of 12 weeks ahead 70% evidence
Exact sum: 20.3 + 9.2 + 4 + 13.2 = 46.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
18The Ensign Group, Inc.ENSG 45.9/100Thin evidence · provisional58% evidence TURNING 18.1/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence 12.2/25 ROCE 2.7% · OPM 9% 76% evidence 9.2/20 P/E 25.1× · PEG — 15% evidence 6.4/20 RS sector -26.6% · RS bench -8.6% · 1Y 8.3%2 of 12 weeks ahead 100% evidence
Exact sum: 18.1 + 12.2 + 9.2 + 6.4 = 45.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
19DaVita Inc.DVA 45.5/100Mixed-negative evidence81% evidence ASLEEP 16.1/35 Revenue 6.7% · PAT -6.9% · OPM change 0.5 pp 83% evidence 13.7/25 ROCE 3.3% · OPM 14.1% 76% evidence 8.2/20 P/E 14.3× · PEG 2.08 65% evidence 7.5/20 RS sector -5.3% · RS bench 14.9% · 1Y 48.9%5 of 12 weeks ahead 100% evidence
Exact sum: 16.1 + 13.7 + 8.2 + 7.5 = 45.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20Pediatrix Medical Group, Inc.MD 45.3/100Mixed-negative evidence74% evidence LEADER 17.7/35 Revenue -2.2% · PAT — · OPM change 1.7 pp 62% evidence 10.1/25 ROCE 2.5% · OPM 8.7% 76% evidence 10.0/20 P/E 10.4× · PEG 1.7 65% evidence 7.5/20 RS sector -10.7% · RS bench 9.7% · 1Y 60.6%12 of 12 weeks ahead 100% evidence
Exact sum: 17.7 + 10.1 + 10 + 7.5 = 45.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21Option Care Health, Inc.this pageOPCH 43.5/100Thin evidence · provisional58% evidence BREAKING OUT 17.3/35 Revenue — · PAT — · OPM change -0.5 pp 45% evidence 11.3/25 ROCE 3.3% · OPM 5.4% 76% evidence 9.9/20 P/E 15.8× · PEG — 15% evidence 5.0/20 RS sector -33.3% · RS bench -16.1% · 1Y -13.6%8 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 11.3 + 9.9 + 5 = 43.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
22Acadia Healthcare Company, Inc.ACHC 42.8/100Thin evidence · provisional58% evidence LEADER 15.1/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence 7.5/25 ROCE 1.1% · OPM 5.8% 76% evidence 9.5/20 P/E 21.2× · PEG — 15% evidence 10.7/20 RS sector -5.6% · RS bench 14.9% · 1Y 27.2%11 of 12 weeks ahead 100% evidence
Exact sum: 15.1 + 7.5 + 9.5 + 10.7 = 42.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
23Select Medical Holdings CorporationSEM 40.3/100Mixed-negative evidence75% evidence 11.0/35 Revenue 5.8% · PAT -20% · OPM change -1.4 pp 83% evidence 9.8/25 ROCE 2% · OPM 6.9% 76% evidence 12.9/20 P/E 15.4× · PEG 0.93 65% evidence 6.6/20 RS sector -23% · RS bench 1.5% · 1Y 9%0 of 1 week ahead to 2026-07-02 70% evidence
Exact sum: 11 + 9.8 + 12.9 + 6.6 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
24Ardent Health, Inc.ARDT 40.2/100Mixed-negative evidence65% evidence BREAKING OUT 14.5/35 Revenue 6.7% · PAT -26.8% · OPM change 0.6 pp 83% evidence 8.8/25 ROCE 1.9% · OPM 5.1% 76% evidence 10.9/20 P/E 9× · PEG — 15% evidence 6.0/20 RS sector -21.3% · RS bench -1.8% · 1Y -16.4%8 of 12 weeks ahead 70% evidence
Exact sum: 14.5 + 8.8 + 10.9 + 6 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
25Astrana Health, Inc.ASTH 39.7/100Mixed-negative evidence81% evidence ASLEEP 14.5/35 Revenue 56.8% · PAT -20.5% · OPM change -0.3 pp 83% evidence 7.4/25 ROCE 2.2% · OPM 3% 76% evidence 10.5/20 P/E 40.2× · PEG 1.17 65% evidence 7.3/20 RS sector -6.8% · RS bench 13.6% · 1Y 35.8%4 of 12 weeks ahead 100% evidence
Exact sum: 14.5 + 7.4 + 10.5 + 7.3 = 39.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
26InnovAge Holding Corp.INNV 38.1/100Thin evidence · provisional58% evidence LEADER 10.8/35 Revenue 14.2% · PAT — · OPM change -6.8 pp 62% evidence 3.6/25 ROCE -8.8% · OPM -11.5% 76% evidence 8.6/20 P/E 103.8× · PEG — 15% evidence 15.1/20 RS sector 8.9% · RS bench 31.1% · 1Y 134.3%12 of 12 weeks ahead 70% evidence
Exact sum: 10.8 + 3.6 + 8.6 + 15.1 = 38.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
27Sonida Senior Living, Inc.SNDA 36.0/100Mixed-negative evidence64% evidence BREAKING OUT 13.0/35 Revenue 25.5% · PAT — · OPM change -20.5 pp 62% evidence 3.8/25 ROCE -1.9% · OPM -23.6% 76% evidence 11.5/20 P/E 1.9× · PEG — 15% evidence 7.7/20 RS sector -12.4% · RS bench 7.5% · 1Y 46.6%7 of 12 weeks ahead 100% evidence
Exact sum: 13 + 3.8 + 11.5 + 7.7 = 36 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
28Surgery Partners, Inc.SGRY 35.1/100Mixed-negative evidence61% evidence ASLEEP 14.2/35 Revenue 5.4% · PAT — · OPM change 0.1 pp 62% evidence 7.2/25 ROCE 0.9% · OPM 8.1% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 3.7/20 RS sector -33.9% · RS bench -17% · 1Y -35.6%5 of 12 weeks ahead 100% evidence
Exact sum: 14.2 + 7.2 + 10 + 3.7 = 35.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
29Brookdale Senior Living Inc.BKD 33.5/100Adverse evidence61% evidence ASLEEP 17.3/35 Revenue -0.4% · PAT — · OPM change 3.2 pp 62% evidence 5.0/25 ROCE 0.9% · OPM 6.8% 76% evidence 10.0/20 P/E — · PEG — 0% evidence 1.2/20 RS sector -29.3% · RS bench -13.2% · 1Y 47.5%1 of 12 weeks ahead 100% evidence
Exact sum: 17.3 + 5 + 10 + 1.2 = 33.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30COMPASS Pathways plcCMPS 48.2/100Thin evidence · provisional47% evidence LEADER 20.0/35 Revenue — · PAT — · OPM change — 33% evidence 5.0/25 ROCE -12.9% · OPM — 61% evidence 10.0/20 P/E — · PEG — 0% evidence 13.2/20 RS sector 23.6% · RS bench 48.2% · 1Y 181.6%11 of 12 weeks ahead 100% evidence
Exact sum: 20 + 5 + 10 + 13.2 = 48.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.

16 · Frequently asked questions

Frequently asked questions

What is Option Care Health, Inc.'s stock price today?

Option Care Health, Inc. trades at $24.5, −13.6% over the past year. The company is valued at $4.0 B. The stock sits at 30% of its 52-week range of $20–$36, −9.3% versus its 200-day average. On the tape, the price is in a downtrend, 21 weeks in. — as of 17 September 2026.

What were Option Care Health, Inc.'s latest quarterly results?

Option Care Health, Inc. reported revenue of $1.4 B and net profit of $0.1 B for the Mar 26 quarter. Revenue rose 1.5% and profit rose 0.0% year on year. Earnings per share were $0.29. The operating margin was 5.2%, 0.8 pp lower than a year earlier. — as of 17 September 2026.

What is Option Care Health, Inc.'s revenue?

Option Care Health, Inc. reported revenue of $1.4 B in the Mar 26 quarter, +1.5% year on year. For the full FY25 fiscal year, revenue was $5.7 B (+13.0%). Over the last 4 years revenue compounded at 13.2% a year. — as of 17 September 2026.

What is Option Care Health, Inc.'s profit?

Option Care Health, Inc. earned $0.1 B of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY25 profit was $0.2 B. The operating margin ran 5.2% in the latest quarter. — as of 17 September 2026.

What is Option Care Health, Inc.'s market cap?

Option Care Health, Inc.'s market capitalisation is $4.0 B at a stock price of $24.5. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.

What is Option Care Health, Inc.'s P/E ratio?

Option Care Health, Inc. trades at a P/E of 18.5×, at the 9th percentile of its own 5-year range, against a long-run median of 25.3×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.

Does Option Care Health, Inc. pay a dividend?

No — Option Care Health, Inc. has declared no dividend per share in any of its last 12 reported quarters, so there is no payout history and no yield to quote. That is a reading of the filed statements, not an estimate. — as of 17 September 2026.

Is Option Care Health, Inc. overvalued?

On its own history, Option Care Health, Inc. looks cheap: its P/E of 18.5× has been cheaper only 9% of the time in 5 years (long-run median 25.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.

Is Option Care Health, Inc. growing?

The picture is mixed for Option Care Health, Inc.: latest-quarter revenue +1.5% year on year, profit +0.0%, and the margin −0.8 pp at 5.2%. The 4-year compound rates are 13.2% (revenue) and 10.7% (profit). The earnings engine currently reads: mixed — as of 17 September 2026.

How is Option Care Health, Inc. performing?

Option Care Health, Inc. is in a downtrend, 21 weeks in. Its latest quarter's revenue rose 1.5% and profit rose 0.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 8 weeks. This describes what the data did, not a rating. — as of 17 September 2026.

What stage is Option Care Health, Inc. in?

Improving — EPS growth bottomed 4 quarters ago at −17.0% and has held its recovery at +4.0%, ROCE holding at 12.2%. The read comes from the last 12 quarters of growth (revenue growth +9.4% latest, profit growth +0.0% latest, eps growth +4.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.

Is Option Care Health, Inc. in an uptrend?

No — the price is in a downtrend (week 21 of stage 4), trading −9.3% versus its 200-day average and at 30% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.

Is Option Care Health, Inc. beating the market?

On recent form, yes — Option Care Health, Inc. has been ahead of the S&P 500 on a trailing-13-week view for 8 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7.1 years the stock moved +110% against the S&P 500's +159% — behind the index over the full window. — as of 17 September 2026.

Will Option Care Health, Inc.'s stock price go up?

This page publishes no price forecast for Option Care Health, Inc. What it measures instead: the stock price is $24.5, the price is in a downtrend 21 weeks in. Its P/E of 18.5× sits at the 9th percentile of its own 5-year range. — as of 17 September 2026.

Is the market betting against Option Care Health, Inc.?

Somewhat — short interest is 8.6% of Option Care Health, Inc.'s tradable float, about 6.0 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.

Does Option Care Health, Inc. have too much debt?

It carries real leverage — Option Care Health, Inc.'s debt-to-equity is 1.01. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.

What is Option Care Health, Inc.'s capex?

Option Care Health, Inc. spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.0 B. — as of 17 September 2026.

What is Option Care Health, Inc.'s cash flow?

Option Care Health, Inc. generated $0.3 B of operating cash flow in FY25 and $0.2 B of free cash flow after $0.0 B of capital spending. Reported profit that year was $0.2 B, so operating cash ran ahead of profit. — as of 17 September 2026.

Is Option Care Health, Inc.'s profit real cash?

Yes — over the last 3 fiscal years, 138% of Option Care Health, Inc.'s reported profit arrived as operating cash. In FY25, operating cash was $0.3 B against reported profit of $0.2 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.

How financially safe is Option Care Health, Inc.?

On the balance sheet, the Z-score reads 3.84 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.

Where is Option Care Health, Inc. in its business cycle?

Option Care Health, Inc.'s FY25 operating margin was 6.0%, against a 5-year band of 5.5%–7.2%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 5.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.

What could break the Option Care Health, Inc. story?

Biggest watch item: the price is not yet in a confirmed uptrend — timing risk, not thesis risk. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.

Is Option Care Health, Inc. a stock worth studying right now?

This is not investment advice. The machine read: Option Care Health, Inc.'s three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.

Sector Alpha — machine-written from the numbers · Data as of 2026-09-17. Every chart on this page is drawn by deterministic code from the raw series — no forecasts, no price opinions, and nothing here is investment advice.

Not SEBI Registered !! Not Investment advice !!

Chat with this pageChat with pageChatChatGPTClaudePerplexityGoogle AI